Articles tagged with Stem Cell Therapy
A meta-analysis of three trials found that CD34+ stem cells improved exercise time by 80.5 seconds and reduced mortality by 24 months in patients with refractory angina. This therapy has been shown to be safe and effective for treating patients with limited options.
A new study reveals that a signal in blood, called Hepatocyte Growth Factor Activator (HGFA), can alert stem cells to heal faster and more efficiently after an injury. By injecting HGFA into mice before an injury, researchers showed improved tissue repair, quicker recovery, and better regeneration of damaged tissues.
A new study found that stem cell therapy reduces lung inflammation in a mouse model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. The treatment also improves lung structure, suggesting it may repair damaged lungs.
Researchers found that a single dose of millions of adult stem cells can aid stroke recovery if given early, reducing destructive inflammation and the risk for serious infections. Early treatment within 36 hours after stroke symptoms surface also showed benefits in physical recovery and reduced disability one year out.
Researchers have identified a mechanism by which the body controls the fate of stem cells, allowing them to adapt and differentiate into various types of cells. This discovery can help improve the effectiveness of stem cell therapies, potentially leading to better treatments for diseases like Parkinson's.
Researchers have identified adipose stem cells as a suitable alternative to bone marrow stem cells for treating orthopedic diseases and injuries in dogs. The study reveals that adipose stem cells exhibit similar functional properties to bone marrow stem cells, including tissue generation and immunomodulation, but grow at a faster rate.
A study of 281 patients with aggressive MS who underwent autologous hematopoietic stem cell transplantation found a 46% five-year progression-free survival rate. Younger age, relapsing form of MS, and fewer prior immunotherapies were associated with better outcomes.
A new nanofiber-on-microfiber matrix enables the scalable expansion of human pluripotent stem cells, resulting in high-quality cells with robust growth. The innovative system allows for easy exchange of nutrients and reduces stress on the cells, making it suitable for large-scale production.
Researchers from Boston University School of Medicine have discovered an efficient way to generate thyroid cells using genetically modified embryonic stem cells. The findings, published in Stem Cell Reports, are the first step towards developing a protocol using human stem cells to model thyroid disease and develop therapies.
High-dose immunosuppressive therapy followed by stem cell transplantation has been shown to induce sustained remission in relapsing-remitting multiple sclerosis. Five years after treatment, 69% of participants had survived without progression or relapse, with some showing improvements in mobility and physical capabilities.
Researchers have developed synthetic stem cells that mimic natural cardiac stem cells, promoting tissue repair and reducing risks of tumor growth and immune rejection. These cells are more durable, can be used off-the-shelf, and can tolerate harsh freezing and thawing.
A deficiency of prohormone covertase (PC1) in the brain is linked to most neuro-hormonal abnormalities in Prader-Willi syndrome. The discovery provides insight into molecular mechanisms underlying the syndrome, highlighting a novel target for drug therapy.
Scientists found that a balance of telomere elongation and trimming in stem cells is necessary for optimal telomere length. Over-elongated telomeres accumulate DNA damage and can lead to cancer. The study deepens understanding of stem cell biology and has implications for regenerative medicine and aging research.
Magenta Therapeutics secures license to transform blood stem cell transplants with new technologies. The suite of technologies could improve the lives of patients with blood diseases and immune disorders.
A recent study published in the journal Stem Cells found that autologous stem cell therapy after traumatic brain injury appears to reduce inflammation and preserve critical brain regions. Researchers used this approach on 25 patients, including those with severe TBI, showing promising results.
Researchers have identified a mechanism by which tumors recruit bone mesenchymal stem cells and convert them into cancer-associated fibroblasts, facilitating tumor progression. Basic fibroblast growth factor (bFGF) signaling plays a crucial role in this process, suggesting new therapeutic targets for suppressing tumor growth.
Researchers at Stanford University School of Medicine discovered that a diet deficient in the amino acid valine can effectively deplete blood stem cells in mice, allowing for successful transplantation. This finding may lead to new ways to treat certain cancers and bone marrow disorders without chemotherapy or radiation therapy.
Researchers at SNPRC have developed an operational technique for delivering neural stem cells to the brain with low invasiveness and high accuracy, targeting the basal ganglia to treat Parkinson's disease. The technique revealed a pulsatile dispersion of injected cells, which could enhance cell survival and efficacy.
A new study reveals the cellular mechanisms that help human mesenchymal stem cells (hMSCs) retain their therapeutic properties when cultured in the lab. Mitochondria play a central role in this process.
Researchers have found a way to restore youthful DNA length in aging cardiac stem cells, improving their ability to form new blood vessels and regenerate heart tissue. The treatment uses a drug to temporarily wake up the cells, making them more responsive to low-oxygen conditions.
Researchers develop a system to selectively destroy undifferentiated pluripotent stem cells (PSCs) using a special dye and light. This approach reduces the risk of teratomas, allowing for safer transplantation and potential treatments for various diseases.
The CHART-1 trial, a large-scale cardiovascular study, investigated the use of bone-marrow stem cells to treat congestive heart failure. Although findings were neutral in the overall patient population, an exploratory analysis identified a sub-group that may benefit from cardiopoietic cell therapy.
Researchers have identified RNA-based biomarkers that distinguish between normal, aging hematopoietic stem cells and leukemia stem cells associated with secondary acute myeloid leukemia. The findings suggest a new way to predict leukemic relapse early and identify potential targets for new drug development.
A new study found that a combination of stem cell grafts and a compound called 3K3A-APC significantly improves motor and sensory functions in mice with stroke-induced brain damage. The therapy increases the production of nerve cells, forming functional connections with the host's nervous system.
Unproven stem cell therapies are on the rise for lung disease patients, despite promise of new treatments. Researchers warn that aggressive marketing and lack of regulation are exacerbating perceptions of these therapies.
The study reveals murky marketing practices and false advertising in the industry, with websites often making unsubstantiated claims about adult stem cells and targeting anti-aging/skincare applications.
A new study published in PLOS Computational Biology suggests that using a specific sub-type of human mesenchymal stem cells can reduce potential risks associated with this therapy. This finding could lead to improved treatment outcomes for heart failure patients, providing a safer alternative to existing therapies.
A Phase II trial suggests that brentuximab vedotin can cure some patients with Hodgkin lymphoma who have relapsed despite previous therapies. The study reports that 13 of 34 patients who achieved complete remission remained disease-free for over five years.
Researchers found that a non-surgical treatment using patient's own bone marrow stem cells improved symptoms and increased physical activity in patients with angina. The treatment involved injecting a 'catalyst' molecule to stimulate stem cell migration into the bloodstream, followed by re-injection of harvested stem cells.
Therapeutic stem cells exit the bloodstream via a distinct process called angiopellosis, where endothelial cells actively push them out of blood vessels. This alternative mechanism allows for longer exit times and multiple cell exits at once, with implications for cancer research and intravenous therapies.
Researchers have identified specific microRNAs that play a crucial role in inducing asthma, providing a potential new target for treatment. The findings suggest that regulating these miRNAs could represent a novel therapeutic approach for asthma.
A new study shows that post-transplant gamma-ray irradiation can prevent immature cells from forming tumors in rat brains after human iPS cell transplantation. This approach aims to improve the safety of cell replacement therapy using human iPS cells for Parkinson's disease treatment.
A Phase II trial found that autologous stem cell transplant is effective and safe for HIV patients with relapsed/treatment-resistant lymphoma. Patients with HIV had comparable overall survival rates and reduced toxicity compared to non-HIV patients.
A randomized Phase III study found nearly 81% of patients in the inotuzumab ozogamicin group achieved complete remission, compared to 31-41% with standard therapies. The drug enabled 41% of patients to proceed with stem cell transplants, increasing their chances of a curative treatment.
A clinical trial showed that stem cells from umbilical cord blood significantly reduced Eczema Area and Severity Index scores by 50% in high-dose patients. Immune-related markers of atopic dermatitis also decreased, with persistent improvement throughout the 12-week follow-up period.
Noninvasive cell-tracking methods enable assessment of stem-cell based therapy safety and efficacy. Current tracking methods for transplanted stem cells include reporter-gene based, exogenous contrast label-based, and multimodel imaging techniques.
A study published in Cell Stem Cell found that small amounts of mitochondrial DNA can override the mitochondria in donor cells after nuclear transfer, raising concerns about the therapy's safety and effectiveness. The researchers are now exploring strategies to avoid this carryover and ensure complete mitochondrial DNA replacement.
A phase 2 clinical trial shows significant benefits from stem cell therapy in patients with class III and IV heart failure. After 12 months, patients receiving the treatment had a lower rate of deaths, cardiovascular hospitalizations, and clinic visits for sudden worsening of heart failure symptoms compared to those receiving a placebo.
A $6.3 million CIRM grant will fund stem cell trials to rescue and restore neurons devastated by ALS. The goal is to extend motor neuron survival, adding years to fulfilling life for patients.
A study by the University of Texas M.D. Anderson Cancer Center reveals that adult stem cells in the prostate basal cell layer express genes similar to those found in deadly prostate cancer, offering a potential new line of treatment for highly aggressive and therapy-resistant forms.
Researchers at Scripps Florida Institute have developed a new method to predict the activity of stem cells in treating various diseases. The Clinical Indications Prediction scale uses TWIST1 levels to determine therapeutic potential, highlighting the importance of considering both angiogenesis and anti-inflammatory effects.
Researchers at St. Jude Children's Research Hospital have identified 17 new genes that regulate hematopoietic stem cell transplantation in mice. The study found that the Foxa3 gene plays a crucial role in repopulating blood-forming stem cells after transplantation, offering hope for improving transplant outcomes and reducing mortality.
Researchers successfully reprogrammed muscle cells from patients with Andersen's syndrome to create induced pluripotent stem (iPS) cells, which can serve as a model for understanding the cause of the rare disorder. The iPS cells demonstrated self-renewal and pluripotency capabilities without affecting the gene mutation known to cause AS.
Researchers developed a potential therapy using adipose-derived stem cells to promote blood vessel growth and revascularization. The study successfully treated animals modeled with CLI, showing improved tissue reperfusion and reduced morbidity.
A study by CNIC researchers has identified a new mechanism through which blood stem cells regulate their proliferation and microenvironment. The protein ESL-1 controls the production of TGF-, a cytokine with antiproliferative properties, and is essential for maintaining HSCs in diseases like anemia.
A clinical trial found that stem cell transplantation did not provide significant improvement in sustained disease remission after one year for patients with difficult-to-treat Crohn's disease. However, some patients showed objective signs of disease disappearance and discontinued active treatment more frequently in the stem cell group.
Researchers found a combination of adult stem cells and parathyroid hormone significantly increased new bone formation in laboratory animals. The therapy also showed enhanced stem cell migration to the area of bone fractures, leading to improved bone density.
A recent study by University of Edinburgh researchers has identified two molecules, Hif-1alpha and Hif-2alpha, that work together to prevent the development of Acute Myeloid Leukemia (AML) in an aggressive type of blood cancer. The findings suggest that therapies designed to block these molecules may have no impact or worsen the disease.
A new study has shown that human embryonic stem cells are fit for use in patients, paving the way for clinical trials of cell therapies. The research also establishes a cost-effective approach for monitoring the quality of stem cell-based products and emerging cell therapies.
Scientists at the University of Edinburgh have developed a new technique for growing liver cells from stem cells using synthetic materials, which could lead to mass production of high-quality cells for patient therapies. The process is cost-effective and eliminates the need for animal products, making treatments safer for patients.
Researchers have developed a new method to genetically correct stem cells in just two weeks, compared to conventional approaches that take over three months. This breakthrough could make personalized stem cell therapies possible for patients with genetic disorders, such as severe combined immunodeficiency and retinal degeneration.
Researchers from the University of Gothenburg and Karolinska Institutet have cast doubt on the effectiveness of stem cell therapy for treating female infertility. The study, published in Nature Medicine, suggests that stem cells cannot generate new egg cells, rendering the treatment unreliable.
A new study by USF researchers suggests that transplanted human bone marrow stem cells preferentially migrate to the spleen, reducing systemic inflammation and secondary brain cell death in post-stroke rats. The anti-inflammatory effects of the stem cells promoted reduced lesions caused by acute stroke.
A new strategy using porous, transplantable hydrogels has experimentally improved bone repair by boosting the survival rate of transplanted stem cells and influencing their cell differentiation. This breakthrough could lead to enhanced regenerative therapies for various tissues and organs.
A multiple myeloma patient experienced complete remission after receiving a personalized cellular therapy called CTL019, which targets cancerous white blood cells. The treatment was combined with chemotherapy and an autologous stem cell transplant, and the patient remains in remission over 12 months after infusion.
A research group in Japan and Korea found that certain dipeptide species support CML stem cell activity. Pharmacological inhibition of nutrient uptake decreased CML stem cell activity in vivo, suggesting a potential therapeutic target for CML therapy. This discovery may provide concrete benefits to patients with CML.
Researchers successfully transplanted mesenchymal stromal cells (MSCs) derived from human amniotic membranes into laboratory mice with oxygen-induced retinopathy, demonstrating the potential of MSCs to suppress causes of diabetic retinopathy and macular degeneration. The study found that AMSCs secrete growth factors that inhibit angiog...
A Phase 1 clinical trial is assessing the safety and activity of a special cell therapy for individuals with complete cervical spinal cord injuries. The therapy uses oligodendrocyte progenitor cells derived from human embryonic stem cells to potentially improve motor or sensory function.
Researchers have identified a protein, NFIX, that promotes the differentiation of neural stem cells into oligodendrocytes, a type of glial cell crucial for protecting neurons. This finding has implications for the development of stem cell-based therapies for brain injury and demyelinating diseases.
Researchers used iPSC-derived renal progenitors to treat acute kidney injury in mice, showing improved recovery with reduced fibrosis and necrosis. The study's findings suggest that paracrine actions of the cells, rather than integration, led to therapeutic effects.